Infliximab in Crohn's disease: early and long-term treatment.

The natural history of Crohn's disease is characterized by a remitting and relapsing course that progresses to complications and surgery in the majority of patients. Current treatment guidelines advocate a stepwise approach according to disease location and severity at presentation, with goals mainly aimed at inducing and maintaining clinical remission. Major advances in the understanding of the pathogenesis of Crohn's disease offered significant opportunities for the development of new therapies over the past years. Infliximab and other biologic agents have shown impressive results in Crohn's disease patients refractory to standard therapy, suggesting a potential disease course-modifying action. These led to the proposal to reverse the traditional therapeutic algorithms using these agents early in the course of the disease. Preliminary data suggest that early intervention may be a more effective treatment strategy in some Crohn's disease patients. As yet, early and indiscriminate use of biologics remains to be supported by convincing evidence. Data on long-term treatment of Crohn's disease with infliximab or other biologics are even more scarce. Future studies aimed to identify predictors of complicated disease and long-term randomized studies aimed to compare "step-up" and "top-down" strategies in high-risk groups should help to answer if early introduction of biological therapy alters the natural history of Crohn's disease.

Porcine living liver transplantation using a vascular prosthesis to replace the intrahepatic vena cava.

BACKGROUND: This study aimed to determine whether the porcine model could be adapted to accommodate living donor liver transplantation (LLT). Because the pig hepatic anatomy precludes a standard approach, a study was designed to evaluate the results using a segment of vascular prosthesis to replace the intrahepatic portion of the inferior vena cava (IVC) with establishment of hepatic venous drainage into the graft. METHODS: A total of 10 LLT were performed using 20 pigs. After left hepatectomy, the intrahepatic IVC was replaced with a modified aorto-iliac prosthesis, anastomosing the proximal (aortic limb) to the infradiaphragmatic IVC, one distal iliac limb to infrahepatic IVC and the other (after shortening) to establish hepatic venous drainage after transplant. Conventional venous bypass was used, and no immunosuppressives were administered. RESULTS: All donors survived the 10-day posthepatectomy observation period. Eight of the 10 transplanted pigs survived at least 2 days (mean 7.6 days; range 3-13 days). No evidence of caval graft thrombosis was observed. CONCLUSIONS: Replacement of the recipient intrahepatic IVC by a vascular prosthesis allows to overcome the major technical obstacle which has limited the use of pigs in LLT.

Effective corneal retrieval in a general hospital. The Royal Melbourne Hospital Eye Bank.

An active program of corneal transplantation depends upon a constant supply of high quality donor tissue. We describe an effective and inexpensive system of corneal donor retrieval in a major teaching hospital, and present an analysis of its donor population. During the five-month period studied in detail (May to October 1991), 365 deaths occurred in the hospital. The relatives of the decreased were contacted and consent for donation was requested after 323 (88.5%) of these deaths. Consent was given in 212 cases (65.5% of requests), with a mean age of the donor population of 69 years. After screening donor tissue for quality, 110 pairs of corneal buttons and 10 globes of sclera were dispatched for surgery during the study period, giving an overall procurement rate of over 30%. Further, the efficient notification and 'on-call' retrieval system led to very rapid corneal retrieval, resulting in an average death to storage medium time of less than two hours.